Investigational drug · Phase 2
0.25% RCI001
Also called: RCI001
Not approved by FDA. In 2 industry-sponsored Phase 2 or 3 trials that are active or finished in the last two years, most often for Dry Eye Disease (DED), Dry Eye.
Phase 2Last checked: Nov 20, 2026Latest source record: Jun 4, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 2
Industry-sponsored trials
Phase 2 and 3 trials
2
2 still active
All registered trials
3
Any phase or sponsor naming "0.25% RCI001"
First trial start
2025
Aug 1, 2025
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "0.25% RCI001", any sponsor or status.
Conditions studied
As listed on its trial records.
- Dry Eye Disease (DED)
- Dry Eye
Approved drugs for the same conditions: Dry eye disease · Ophthalmology
Largest trials
Live from ClinicalTrials.gov: studies naming "0.25% RCI001" as an intervention, largest first.
- A Study Evaluating the Efficacy and Safety of RCI001 Ophthalmic Solution Compared to Placebo in Subjects With Dry EyePivotal-lookingNot yet recruiting
ORA, Inc.Industry
NCT07068958 · 200 participants (planned) · Start Aug 1, 2025 · Primary completion Nov 1, 2025
Drug: 0.25% RCI001 Ophthalmic Solution; Placebo Ophthalmic Solution (vehicle) · For: Dry Eye Disease (DED)
- A Phase 2 Study of RCI001 Ophthalmic Solution in Participants With Dry Eye DiseasePivotal-lookingNot yet recruiting
RudacureIndustry
NCT07625124 · 200 participants (planned) · Start Sep 1, 2027 · Primary completion Jun 30, 2028
Drug: RCI001 Ophthalmic Solution; Placebo Ophthalmic Solution · For: Dry Eye
RudacureIndustry
NCT07640867 · 40 participants · Start Oct 28, 2024 · Primary completion Aug 29, 2025
Drug: RCI001 Eye Drops 0.25%; Placebo Eye Drops · For: Dry Eye
Sites: Seoul, South Korea
Newest research
PubMed records naming it or its code names, newest first.
- Efficacy of RCI001 as a Therapeutic Candidate in a Primary Sjögren Syndrome Mouse Model.
Kang H, Jung YH, Moon J, et al. · Cornea 2025
- Efficacy of RCI001 as a therapeutic candidate of dry eye disease in a modified mixed dry eye model.
Jung YH, Ku YA, Moon J, et al. · Eye Vis (Lond) 2024
- Comparison of RCI001 and corticosteroid on the effects on intraocular pressure in mice.
Kim SH, Ku YA, Yoo C, et al. · Front Med (Lausanne) 2023
- Comparison of Corneal Epithelial Wound Healing between Topical RCI001, Solcoseryl, and Polydeoxyribonucleotide in the Murine Ocular Alkali Burn Model.
Song MS, Ku YA, Kim S, et al. · Korean J Ophthalmol 2023
- Ocular Distribution and Pharmacokinetics of 8-Oxo-2'-Deoxyguanosine: A Novel Therapeutic Candidate of Ocular Surface Diseases.
Chung H, Ha Y, Kim YH, et al. · J Ocul Pharmacol Ther 2022
- Investigating the Anti-Inflammatory Effects of RCI001 for Treating Ocular Surface Diseases: Insight Into the Mechanism of Action.
Kim S, Jang YW, Ku YA, et al. · Front Immunol 2022
Also in development for Dry Eye Disease (DED)
- DFL24498Phase 32 trials
Dompé Farmaceutici S.p.A · Dry Eye Disease (DED), Atopic Keratoconjunctivitis
- licaminlimabPhase 31 trial
Oculis · Dry Eye Disease (DED)
- TTAX03Phase 22 trials
BioTissue Holdings, Inc · Knee Osteoarthritis, Knee Pain Chronic, Knee Arthritis
- BRM421Phase 21 trial
BRIM Biotechnology Inc. · Dry Eye Disease (DED), Keratoconjunctivitis Sicca
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.